Evidence map›Paper›PMID 37292761›Full record

ArticlebioRxiv : the preprint server for biology2023

A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production.

Shamus P Keeler, Kangyun Wu, Yong Zhang, Dailing Mao, Ming Li, Courtney A Iberg, Stephen R Austin, Samuel A Glaser, Jennifer Yantis, Stephanie Podgorny and 6 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Shamus P KeelerPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Kangyun WuPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Yong ZhangPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Dailing MaoPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Ming LiPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Courtney A IbergPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Stephen R AustinNuPeak Therapeutics Inc., St. Louis, MO 63105.
Samuel A GlaserPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Jennifer YantisPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Stephanie PodgornyPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Steven L BrodyPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Joshua R ChartockPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Zhenfu HanPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Derek E ByersPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Arthur G RomeroPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Michael J HoltzmanPulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.

Funding

Defining and Controlling Airway DiseaseR35HL145242 · NHLBI · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2019 to 2025
$6.6M
PARP9-DTX3L Control Of Viral Infection and Airway DiseaseR01AI130591 · NIAID · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2017 to 2021
$3.0M
Preclinical Development of an Anti-Mucus DrugUH2HL123429 · NHLBI · WASHINGTON UNIVERSITY · PI HOLTZMAN, MICHAEL J · 2014 to 2015
$3.0M
A New Small-Molecule Kinase Inhibitor for Airway DiseaseR41HL149523 · NHLBI · NUPEAK THERAPEUTICS, INC. · PI HOLTZMAN, MICHAEL J · 2019 to 2019
$300k
NHLBI NIH HHS R35 HL145242NHLBI NIH HHS R41 HL149523NHLBI NIH HHS UH2 HL123429NIAID NIH HHS R01 AI130591
6 · The paper itself

Abstract

Common respiratory diseases continue to represent a major public health problem, and much of the morbidity and mortality is due to airway inflammation and mucus production. Previous studies indicated a role for mitogen-activated protein kinase 14 (MAPK14) in this type of disease, but clinical trials are unsuccessful to date. Our previous work identified a related but distinct kinase known as MAPK13 that is activated in respiratory airway diseases and is required for mucus production in human cell-culture models. Support for MAPK13 function in these models came from effectiveness of

Indexed as

asthmachronic obstructive pulmonary disease (COPD)drug discoveryminipig modelrespiratory viral infection

Identifiers

PMID37292761
PMCPMC10246002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.